Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease  Nina Dickerhof, Rufus Turner, Irada Khalilova, Emmanuelle Fantino,

Slides:



Advertisements
Similar presentations
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Christopher C. Miller, Christopher A
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Zachary M. Sellers, Lori McGlocklin, Andrea Brasch 
Anna L. P. Chapman, Brian M. Morrissey, Vihas T. Vasu, Maya M
Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Successful treatment of cepacia syndrome
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
John Widger, Sarath Ranganathan, Philip J. Robinson 
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
A. Oliver, A. Mena  Clinical Microbiology and Infection 
Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection  Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Evaluation of salt supplementation in CF infants
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
Vitamin A and lung function in CF
A.H. Gifford  Journal of Cystic Fibrosis 
Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis  Elizabeth F. Shead, Charles S. Haworth,
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Small macrophages are present in early childhood respiratory disease
Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India  Shivaram S. Shastri, Madhulika Kabra, Sushil.
Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis 
Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J
Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis  Christopher R. Sudfeld, Elliott C. Dasenbrook, William.
Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function  Julia Seyfarth, Sutharsan Sivagurunathan,
Cytokine gene polymorphisms and severity of CF lung disease
Nasal polyposis in lung transplant recipients with cystic fibrosis
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention  H. White, K. Pollard, C. Etherington, I. Clifton,
Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire  Joän M. Patterson, Melanie Wall, Jerica.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Higher risk of hospitalization among females with cystic fibrosis
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Determining presence of lung disease in young children with cystic fibrosis: Lung clearance index, oxygen saturation and cough frequency  E.M. Bakker,
Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage  Luke J. Berry, Barbara Sheil, Luke Garratt,
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Soluble inflammation markers in nasal lavage from CF patients and healthy controls  Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis  Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
CFTR modulators and pregnancy: Our work has only just begun
Beta-lactam allergy in adults with cystic fibrosis
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P
Anne K. Swisher, Kathryn Moffett, Linda Baer 
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease  Nina Dickerhof, Rufus Turner, Irada Khalilova, Emmanuelle Fantino, Peter D Sly, Anthony J Kettle  Journal of Cystic Fibrosis  Volume 16, Issue 2, Pages 214-221 (March 2017) DOI: 10.1016/j.jcf.2016.10.012 Copyright © 2016 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Relationship between oxidative biomarkers and MPO in BAL. The relationship between a) GSA, b) allantoin, c) methionine sulfoxide and d) 3-chlorotyrosine and MPO protein in BAL from children with CF. Data were analysed using a Pearson product–moment correlation. Methionine sulfoxide is reported as the percent of total methionine species and 3-chlorotyrosine as 3-chlorotyrosines (Cl-Tyr) per 1000 tyrosines (Tyr). The smaller sample set for methionine sulfoxide and 3-chlorotyrosine is a result of limited sample availability. Journal of Cystic Fibrosis 2017 16, 214-221DOI: (10.1016/j.jcf.2016.10.012) Copyright © 2016 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Effect of infection on biomarkers of neutrophilic inflammation in BAL. Children with CF were split into those that were uninfected (−Inf), infected with Pseudomonas aeruginosa (+PsA) and infected with any organism other than PsA (+Inf) and the concentration in BAL of a) MPO protein, b) GSA, c) allantoin, d) methionine sulfoxide and e) 3-chlorotyrosine was determined. Methionine sulfoxide is reported as the percent of total methionine species and 3-chlorotyrosine as 3-chlorotyrosines (Cl-Tyr) per 1000 tyrosines (Tyr). The smaller sample set for methionine sulfoxide and 3-chlorotyrosine is a result of limited sample availability. Individual values are shown by symbols and the mean is represented by the bar±SEM. Mann–Whitney rank test: ⁎P<0.05, ⁎⁎P<0.01 compared with the uninfected group. Journal of Cystic Fibrosis 2017 16, 214-221DOI: (10.1016/j.jcf.2016.10.012) Copyright © 2016 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Effect of infection and bronchiectasis on serum GSA and allantoin in children with CF. Children with CF were split into those that were uninfected (−Inf), infected with Pseudomonas aeruginosa (+PsA) and infected with any organism other than PsA (+Inf) and the serum concentration of (a) GSA and (b) allantoin was determined. Children were split into those with (+) and without (−) bronchiectasis (bronc) and the serum concentration of (c) GSA and (d) allantoin was determined. The smaller sample set for allantoin is a result of limited sample availability. Bronchiectasis data was not always available accounting for the smaller sample set in c) and d) compared to a) and b). Individual values are shown by symbols and the mean is represented by the bar±SEM. Mann–Whitney rank test: ⁎P<0.05, compared with the uninfected group. Journal of Cystic Fibrosis 2017 16, 214-221DOI: (10.1016/j.jcf.2016.10.012) Copyright © 2016 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Effect of infection and bronchiectasis on urinary GSA and allantoin in children with CF. Children with CF were split into those that were uninfected (−Inf), infected with Pseudomonas aeruginosa (+PsA) and infected with any organism other than PsA (+Inf) and a) GSA and b) allantoin was determined. Children were split into those with (+) and without (−) bronchiectasis (bronc) and the urinary concentration of c) GSA and d) allantoin was determined. The smaller sample set for allantoin is a result of limited sample availability. Bronchiectasis data was not always available accounting for a smaller sample set in c) and d) compared to a) and b). Concentrations were normalized using specific gravity ratios. Individual values are shown by symbols and the mean is represented by the bar±SEM. Mann–Whitney rank test: ⁎P<0.05 compared with the uninfected group. Journal of Cystic Fibrosis 2017 16, 214-221DOI: (10.1016/j.jcf.2016.10.012) Copyright © 2016 European Cystic Fibrosis Society Terms and Conditions